• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    3.830 -0.120 (-3.04%)
    Streaming Delayed Price Updated: 10:20 AM EDT, Jun 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 46,499
    Open 4.010
    Bid (Size) 3.820 (200)
    Ask (Size) 3.850 (500)
    Prev. Close 3.950
    Today's Range 3.812 - 4.090
    52wk Range 1.110 - 5.744
    Shares Outstanding 11,184,423
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
    Via ACCESS Newswire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer
    Via Investor Brand Network
    Topics Artificial Intelligence

    Performance

    YTD
    +23.2%
    +23.2%
    1 Month
    +13.3%
    +13.3%
    3 Month
    +72.5%
    +72.5%
    6 Month
    +14.7%
    +14.7%
    1 Year
    +19.3%
    +19.3%

    More News

    Read More
    News headline image
    Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
    Via ACCESS Newswire
    News headline image
    Lantern Pharma (LTRN) Q1 2025 Earnings Transcript ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Support for HARMONIC(TM) Trial Amendments in Never-Smoker NSCLC
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q1 2026 Results, Advances Clinical Pipeline and AI Commercialization Strategy
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4.4 Million Registered Direct Offering
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
    From Lantern Pharma Inc.
    Via Business Wire
    MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Report First Quarter 2026 Financial Results May 15
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands withZeta.ai Roadmap With Multi-Agent AI and Computational Biology Tools
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
    From Lantern Pharma Inc.
    Via Business Wire
    MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host Live Public Demo of withZeta.ai AI Co-Scientist Platform
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers
    Via ACCESS Newswire
    News headline image
    Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.ai - A Platform to Conquer Rare Cancers
    Via ACCESS Newswire
    News headline image
    Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
    From Lantern Pharma Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Lantern Pharma Inc. - Common Stock publicly traded?
    Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
    What exchange does Lantern Pharma Inc. - Common Stock trade on?
    Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
    The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
    What is the current price of Lantern Pharma Inc. - Common Stock?
    The current price of Lantern Pharma Inc. - Common Stock is 3.830
    When was Lantern Pharma Inc. - Common Stock last traded?
    The last trade of Lantern Pharma Inc. - Common Stock was at 06/25/26 10:20 AM ET
    What is the market capitalization of Lantern Pharma Inc. - Common Stock?
    The market capitalization of Lantern Pharma Inc. - Common Stock is 42.84M
    How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
    Lantern Pharma Inc. - Common Stock has 43M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.